Response to platinum-based therapy is a major prognostic factor in epithelial ovarian cancer (EOC) and reliable prognostic biomarkers are urgently needed to identify patients at high risk. Since ligands of the Programmed Death Receptor-1 (PD-L1 and PD-L2) play a crucial role within the tumor microenvironment for tumorigenesis, we investigated levels of sPD-L1 and sPD-L2 in liquid biopsies of serum samples, and correlated the results with the clinical status, presence of circulating tumor cells (CTCs) and disease outcome in primary EOC patients. sPD-L1 and sPD-L2 were determined by ELISA in patients ( = 83) and healthy females ( = 29). Gene expression analysis of EpCAM, MUC-1, CA-125, and ERCC1 was performed by RT-PCR after CTCs enrichment. sPD-L1 was significantly ( = 0.0001) increased and sPD-L2 decreased ( = 0.003) in EOC patients compared to controls. While enhanced sPD-L1 was associated with residual tumor burden ( = 0.022), reduced sPD-L2 levels were related to platinum-resistance ( < 0.01) and the presence of ERCC1+ CTCs ( < 0.0001). High sPD-L1 levels were associated with a reduced 5 year overall survival (OS, = 0.003) and progression-free survival (PFS, = 0.019). Strikingly, sPD-L1 levels >6.4 pg/ml were indicative of a reduced OS ( = 0.035) and PFS ( = 0.083) in platinum-sensitive patients, while OS and PFS in platinum-resistant patients did not differ when patients were stratified to this cut-off. Our study highlights sPD-L1 and sPD-L2 as complementary biomarkers reflecting clinical status, treatment response and disease outcome of EOC patients. Especially, sPD-L1 may facilitate the identification of high-risk patients with unfavorable disease outcomes despite platinum-sensitivity arguing for additional therapeutic approaches. As sPD-L1 and sPD-L2 are easily accessible via liquid biopsy, the inclusion of sPD-L1 and sPD-L2 in addition to CTC investigation as markers for risk assessment during patient therapy planning and follow-up appears to be a valuable approach.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803523 | PMC |
| http://dx.doi.org/10.3389/fonc.2019.01015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Urinary soluble PD-1 as a biomarker of checkpoint inhibitor-induced acute tubulointerstitial nephritis.
Clin Kidney J
August 2024
Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
Background: Acute interstitial nephritis (AIN) related to immune checkpoint inhibitors (ICI-AIN) has a not completely understood pathophysiology. Our objectives were to analyze possible biomarkers for the differentiation between acute tubular necrosis (ATN) and AIN, especially in cancer patients, and to study the participation of the immune checkpoint pathway in ICI-AIN.
Methods: We performed an observational study.
Persistence of lung structural and functional alterations at one year post-COVID-19 is associated with increased serum PD-L2 levels and altered CD4/CD8 ratio.
Immun Inflamm Dis
July 2024
Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.
Background: Persistent respiratory symptoms and lung abnormalities post-COVID-19 are public health problems. This study evaluated biomarkers to stratify high-risk patients to the development or persistence of post-COVID-19 interstitial lung disease.
Methods: One hundred eighteen patients discharged with residual lung abnormalities compatible with interstitial lung disease (COVID-ILD patients) after a severe COVID-19 were followed for 1 year (post-COVID-ILD patients).
Evaluation of soluble co-inhibitors and co-stimulators levels of the immune response in gastric cancer.
J Surg Oncol
September 2024
Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
Article Synopsis
- The study investigates the levels of various soluble immune mediators in gastric cancer (GC) patients compared to healthy controls, focusing on potential therapeutic targets for treatment.
- Results indicate low levels of sPD-1, sPD-L2, and sGal9, while levels of sPD-L1, sTIM-3, sGITR, and sGITRL were higher in GC patients, with variations based on cancer stages and specific tumor locations.
- Findings suggest a potential link between certain soluble mediators (sPD-1, sTIM-3, sGal9) and disease progression, as well as the association of low sGITR with increased mortality within the first
Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.
Curr Oncol
March 2024
Department of Urology, Kurume University School of Medicine, Kurume 830-0011, Japan.
Immuno-oncology (IO) combination therapy is the first-line treatment for advanced renal cell carcinoma (RCC). However, biomarkers for predicting the response to IO combination therapy are lacking. Here, we investigated the association between the expression of soluble immune checkpoint molecules and the therapeutic efficacy of IO combination therapy in advanced RCC.
View Article and Find Full Text PDFsPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
Cytokine
April 2024
The Aoyang Cancer Institute, The Affilated Aoyang Hospital of Jiangsu University, Zhangjiagang, 215600 Jiangsu, China. Electronic address:
Introduction: Lung cancer is the leading cause of cancer death worldwide. We aim here to determine the soluble programmed death ligand-1 (sPD-L1) and soluble programmed death ligand-2 (sPD-L2) levels in the plasma of patients with lung cancer and evaluate the clinical significance.
Methods: Plasma samples from 95 lung cancer patients and 55 healthy donors were collected, and the sPD-L1 and sPD-L2 levels were measured using the enzyme-linked immunosorbent assay.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!